Antibiotic resistance: what is a viable business model? – news

Our events



The Covid-19 pandemic underscored the urgency of developing treatments and vaccines against emerging infections. The opportunity to re -launch antibiotic resistance. But for that, the speakers of the symposium’s second round table Pharmaceuticals
in infectious diseases came to testify to the need to develop a viable business model for manufacturers.

“If France is to be proactive in combating antibiotic resistance in establishing a system for monitoring antibiotic consumption and related resistance, the consequences must be drawn earlier, drew Dr Jean Carlet, honorary president of Alliance against the development of multi-resistant bacteria, and president of the 2015 ministerial task force on the protection of antibiotics, at the opening of the second round table of the colloquium of Pharmaceuticals focused on infectious diseases. But the Covid-19 crisis has alerted citizens of microbial transmission, and antibiotic resistance is now a topic we can talk about, “he said with pleasure. However, the current business model, which associates profits in sales volume, is not an incentive for investment in the industry. “The problem of antibiotic resistance is that to fund the development of new antibiotics we will do everything to ensure that they are not underused”, explains Pierre Dubois, professor of economics at the Toulouse School of Economics, who observes decades of drainage. up the innovation pipeline in this sector.

Low price, low quantity

The equation is not profitable for manufacturers. But there is an urgent need to act, as underlined Philippe Lamoureux, Managing Director of Leem and Vice President of IFPMA: “By 2050, antibiotic resistance could claim up to 10 million victims per year and cost up to 100,000 billion dollars to the Mondial economy. He laments that 43 only antibiotics are currently produced worldwide. “Of the manufacturers who have ventured to develop antibiotics over the past ten years, a third of them are no longer available, sold or even had to change their business model”, he pointed out. he. Awareness is happening and things are changing. 23 pharmaceutical companies, in partnership with the European Investment Bank (EIB), WHO and Wellcome Trust, have invested in the AMR-Action Fund supported by IFPMA. “This is a grant fund. of 1 billion dollars aimed at developing, by 2030, two to four new antibiotics to respond to an unresolved public health problem ” , industrialist report. . After a call for tenders and review of applications by a jury, two preliminary projects were selected: Adaptive Phage Therapeutics (APT), which develops a library of phages, and Venatorx Pharmaceuticals, which develops beta-lactams inhibitors. /beta- lactamases that target drug-resistant Gram-negative bacteria.

Adapt business models

A Van Gerven, Director of the Hospital Division of Pfizer France, agrees with the need for change in the field. Pfizer has three antibiotics in its pipeline, the development of which it wants to undertake over five years. “The group also makes specific alliances,” he said. The levers are the prevention of antibiotic resistance by implementing monitoring and diagnostic tools, promoting good use, and using new economic models. “One of the solutions is to remove the link between revenue and the quantity of products sold,” Pierre Dubois asked. This is called the subscription model, independent of consumption. “It helps attract investment to the industry, but it’s expensive to implement,” he rages. Another solution is to transfer the exclusive patent rights of a newly approved antimicrobial to another product that has already been marketed, from the manufacturer’s portfolio holding the MA or a third party, in any therapeutic area. Experiments that should prove their value as soon as possible.

Juliette Badina

Leave a Comment